These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 39392888)

  • 1. Mechanism of degrader-targeted protein ubiquitinability.
    Crowe C; Nakasone MA; Chandler S; Craigon C; Sathe G; Tatham MH; Makukhin N; Hay RT; Ciulli A
    Sci Adv; 2024 Oct; 10(41):eado6492. PubMed ID: 39392888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of PROTAC cooperative recognition for selective protein degradation.
    Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
    Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
    Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
    J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
    Paltoglou S; Roberts BJ
    Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
    Diehl CJ; Ciulli A
    Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate.
    Roy MJ; Winkler S; Hughes SJ; Whitworth C; Galant M; Farnaby W; Rumpel K; Ciulli A
    ACS Chem Biol; 2019 Mar; 14(3):361-368. PubMed ID: 30721025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation.
    Huang Y; Yokoe H; Kaiho-Soma A; Takahashi K; Hirasawa Y; Morita H; Ohtake F; Kanoh N
    Bioconjug Chem; 2022 Jan; 33(1):142-151. PubMed ID: 34878263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted protein degradation via intramolecular bivalent glues.
    Hsia O; Hinterndorfer M; Cowan AD; Iso K; Ishida T; Sundaramoorthy R; Nakasone MA; Imrichova H; Schätz C; Rukavina A; Husnjak K; Wegner M; Correa-Sáez A; Craigon C; Casement R; Maniaci C; Testa A; Kaulich M; Dikic I; Winter GE; Ciulli A
    Nature; 2024 Mar; 627(8002):204-211. PubMed ID: 38383787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
    Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
    Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen-Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design.
    Eron SJ; Huang H; Agafonov RV; Fitzgerald ME; Patel J; Michael RE; Lee TD; Hart AA; Shaulsky J; Nasveschuk CG; Phillips AJ; Fisher SL; Good A
    ACS Chem Biol; 2021 Nov; 16(11):2228-2243. PubMed ID: 34582690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
    Zengerle M; Chan KH; Ciulli A
    ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analyses for effects of neddylation on CRL2
    Wang K; Reichermeier KM; Liu X
    Protein Sci; 2021 Nov; 30(11):2338-2345. PubMed ID: 34459035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for lysine specificity in the yeast ubiquitin-conjugating enzyme Cdc34.
    Sadowski M; Suryadinata R; Lai X; Heierhorst J; Sarcevic B
    Mol Cell Biol; 2010 May; 30(10):2316-29. PubMed ID: 20194622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and structural insight into lysine selection on substrate and ubiquitin lysine 48 by the ubiquitin-conjugating enzyme Cdc34.
    Suryadinata R; Holien JK; Yang G; Parker MW; Papaleo E; Šarčević B
    Cell Cycle; 2013 Jun; 12(11):1732-44. PubMed ID: 23656784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
    Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Chen J; Corr N; Dela Cruz-Chuh J; Del Rosario G; Fullerton A; Hartman SJ; Jiang F; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Lu Y; Mulvihill MM; Murray JM; O'Donohue A; Rowntree RK; Sawyer WS; Staben LR; Wai J; Wang J; Wei B; Wei W; Xu Z; Yao H; Yu SF; Zhang D; Zhang H; Zhang S; Zhao Y; Zhou H; Zhu X
    J Med Chem; 2021 Mar; 64(5):2576-2607. PubMed ID: 33596073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
    Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Bhakta S; Blaquiere N; Chen J; Dela Cruz-Chuh J; Gascoigne KE; Hartman SJ; He M; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Liu L; Liu Q; Lu Y; Meng F; Mulvihill MM; O'Donohue A; Rowntree RK; Staben LR; Staben ST; Wai J; Wang J; Wei B; Wilson C; Xin J; Xu Z; Yao H; Zhang D; Zhang H; Zhou H; Zhu X
    J Med Chem; 2021 Mar; 64(5):2534-2575. PubMed ID: 33596065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.
    Foley CA; Potjewyd F; Lamb KN; James LI; Frye SV
    ACS Chem Biol; 2020 Jan; 15(1):290-295. PubMed ID: 31846298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.